- Record: found
- Abstract: found
- Article: not found
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.
Eric Winquist
1 ,
Malcolm J Moore ,
Kim N Chi ,
D Scott Ernst ,
Hal Hirte ,
Scott North ,
Jean Powers ,
Wendy Walsh ,
Therese Boucher ,
Robert Patton ,
Lesley Seymour
May 24 2005
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Protein farnesylation by farnesyltransferase (FTase) is required for membrane localization and effective signal transduction by G-proteins, including Ras. Lonafarnib inhibits FTase and has shown antitumor activity in both preclinical and clinical settings. As disturbances in Ras signaling pathways have been implicated in the pathogenesis of transitional cell carcinoma (TCC), the antitumor activity of lonafarnib was studied in a National Cancer Institute of Canada Clinical Trials Group Phase II trial in patients with previously treated TCC.